India's first mover in
neurological protective MedTech.
12 million epilepsy patients. 140 million elderly at fall risk. 0 CDSCO-registered competitors. DazzleSafe™ is not a product in a crowded market — it is creating the market. We are raising to fund clinical validation, CE MDR certification, and international scale.
A critical category.
No credible incumbent.
India's neurological protective headgear market is structurally underserved. No CDSCO-registered, clinically-positioned, affordably priced soft helmet exists from any domestic or international manufacturer. DazzleSafe™ is building this category from first principles.
Organic growth.
Zero paid marketing.
All commercial traction to date has been achieved without any paid marketing. This is the clearest signal of genuine clinical demand — patients, caregivers, and neurologists finding the product through word-of-mouth and clinical prescription.
TRL 7 to TRL 9
and beyond.
The C-CAMP WIN CoE grant project takes DazzleSafe™ from a commercially proven TRL 7 product to a clinically validated, internationally certified, institutionally adopted TRL 9 medical device — unlocking the next phase of scale.
Capital-efficient
non-dilutive pathway.
The project has been entirely self-funded by the Founder to date — demonstrating genuine commitment and validating market demand without external capital. The funding stack is built to maximise non-dilutive grant funding before equity investment.
Interested in DazzleSafe™
as an investment opportunity?
We are currently in discussions with strategic investors in the MedTech and neurological health space. Investor deck and financials available under NDA.